Downregulation of HIV-1 vif by a hammerhead ribozyme expressed
from a retroviral vector
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HIV infection of CD4 + T helper cells results in a gradual deterioration of immune function and leads to the onset of the
Acquired Immune Deficiency Syndrome (AIDS). Current research suggests that HIV infection may be combated with ribozyme
therapy. Hammerhead ribozymes are small, catalytic RNAs that can be designed to cleave substrate RNAs at specific
sequences, and those targeted to HIV-1 mRNAs have been shown to greatly reduce or inhibit viral replication. The HIV-1
virion infectivity factor (vif) gene encodes a protein that counteracts an innate, antiretroviral defense mechanism of nonpermissive CD4 + T helper cells. This mechanism is mediated by apolipoprotein B mRNA-editing enzyme-catalytic
polypeptide-like 3G (APOBEC3G), a cellular cytidine deaminase that is encapsulated into assembling virions in the absence of
vif and is inhibitory during the next round of viral replication. Vif neutralizes APOBEC3G by reducing its translation and by
rapid degradation of the native protein. Vif mRNA, therefore, may be a good target for ribozyme mediated inhibition of HIV-1
replication. To test this hypothesis a catalytic hammerhead ribozyme targeted to nucleotide 5113 of the HIV-1 genomic clone
NL43 (Accession # M19221) was designed and synthesized. A non-catalytic control, Vif5113∆ was also designed and
synthesized. Vif5113 and Vif5113Δ were cloned into the retroviral vector, pSuper.retro.puro (pSRP) to facilitate tissue culture
studies. In this study, Vif5113 and Vif113Δ ribozymes were analyzed for their ability to reduce vif expression in an
intracellular cleavage assay. These studies, as determined by Western blot analysis, suggested that vif expression was reduced
in the presence of the catalytic ribozyme Vif5113.
expression in infected cells would reconstitute the normal
antiviral activity of APOBEC3G. Previous research suggested
Introduction
that HIV infection may be combated with ribozyme therapy (11HIV-1 is a retrovirus that infects CD4+ T helper cells
13). Hammerhead ribozymes are small, catalytic RNAs that can
(1;2) resulting in a gradual deterioration of immune function and
be designed to target and cleave substrate RNAs at sequence
eventually leading to the onset of the Acquired Immune
specific sites (14). These ribozymes cleave mRNAs at the target
Deficiency Syndrome (3-6). In December 2007, the World
sequence XUX’ where X is A, C, G, or U and X’ is A, C, or U
Health UNAIDS Organization estimated that 33 million people
(15). In this report, a hammerhead ribozyme targeted to HIV-1
worldwide were living with HIV/AIDS. It was also estimated
vif was designed and cloned into the retroviral vector,
that 14,000 people worldwide become newly infected with the
pSuper.retro.puro (16;17). This vector was chosen due to its
Human Immunodeficiency Virus (HIV) every day (7).
ability to express siRNAs from the RNA Polymerase III H1
The HIV-1 genome encodes nine viral genes from
promoter, and we hypothesized that it would also efficiently
which fifteen functional gene products are expressed (8). One of
express ribozymes. As a control, a non-catalytic ribozyme
these genes, the virion infectivity factor (vif) encodes a 23 kD
targeted to the same HIV-1 vif sequence was designed and
protein that counteracts an innate, antiretroviral defense
cloned. These constructs were tested for their antiviral activity in
+
mechanism of CD4 T helper cells (9), the primary target of HIV
a vif inhibition assay. These results suggested that vif expression
(2). This resistance to HIV infection is due to the expression of
was reduced in the presence of a hammerhead ribozyme.
APOBEC3G (human apolipoprotein B mRNA-editing enzyme
catalytic polypeptide-like 3G), which acts to inhibit reverse
Materials and Methods
transcription of retroviruses (8).
APOBEC3G expression is stimulated by certain viral
Cloning
The HIV-1 NL43 vif sequence (Accession number
proteins such as HIV-1 Vif.
Normally, APOBEC3G is
M19921) was analyzed for the presence of potential hammerhead
encapsulated into progeny virions, where it remains noncleavage sites (15). One such sequence, a pGUA was located at
functional until the virion infects its host cell. Upon infection of
nucleotide 5113. This sequence along with its immediate
the host cell and reverse transcription of the viral genome,
flanking sequences were used to generate a hammerhead
APOBEC3G induces hypermutation from C to U in the minus
ribozyme according to the Haseloff and Gerlach model (14). A
strand of viral DNA resulting in G to A mutations in the positive
non-catalytic control ribozyme was generated by an A to G
sense DNA strand. These mutations in the viral genome inhibit
substitution within the ribozyme catalytic core (12) (Figure 1).
normal expression of viral genes and render the target cell
incapable of producing progeny virions and facilitating a
productive infection (8).
Vif counteracts this activity by binding APOBEC3G
and targeting the protein for degradation through the ubiquitin
pathway (10).
We hypothesized that downregulating vif
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expressed from pCMV-Vif FLAG, which encodes the HIV-1
NL43 vif gene fused to the FLAG epitope (20). pSRP5113 was
transfected at a 1:1 (ribozyme to vif) or 2:1 (ribozyme to vif)
plasmid ratio. The 1:1 ratio mixtures consisted of 5 µg of
pSRP5113 or pSRP5113∆ and 5 µg of pCMV-VifFLAG, for a
total of 10 µg DNA. The 2:1 ratio mixtures consisted of 10 µg of
either pSRP5113 or pSRP5113∆ and 5 µg of pCMV-VifFLAG,
for a total of 15 µg DNA.

Figure 1. Hammerhead ribozyme design. Vif RNA containing the pGUA
cleavage site at nucleotide 5113 is shown annealed to the ribozyme
flanking regions. An A to G mutation in the catalytic core converted the
ribozyme to a non-catalytic form.

The Vif5113 and Vif5113∆ ribozymes were
synthesized (5’ACA TAT GGT GTT TCT GAT GAG TCC GTG
AGG ACG A/GAA CTA ATC TTT TCC AT 3’) and cloned into
the shuttle vector pPCR-Script (Stratagene) as previously
described (18). Correct insertion of the ribozyme in the resulting
plasmids pVif5113 and pVif5113∆ was verified by sequencing.
To study ribozyme-mediated anti-Vif activity in cell
culture, each ribozyme was moved into the retroviral vector,
pSuper.retro.puro (Oligoengine). For this ribozyme-specific
primers were designed and synthesized to include HindIII and
BglII restriction sites: Vif5113BglII Forward (5’ ATT AGA TCT
ACA TAT GGT GTT TCT GAT GAG 3’) and Vif5113HindIII
Reverse (5’ ATT AAG CTT ATG GAA AAG ATT AGT TTC G
3’). Each ribozyme was amplified using Vent DNA Polymerase
(New England Biolabs) and re-cloned into pPCR-Script. The
BglII/HindIII ribozyme fragments from each of the resulting
plasmids were gel purified and cloned into the similarly digested
pSuper.retro.puro vector. Accurate cloning was verified by
sequencing and the resulting retroviruses, pSRPVif5113 and
pSRPVif5113∆, were analyzed for their anti-vif activity.
Cells and Transfection
293T cells were maintained in Dulbecco’s Modification
of Eagle’s medium (DMEM) supplemented with 10% Fetal
Bovine Serum (Atlanta Biologicals) in a humidified 37°C
incubator with 5% CO 2 . All transfections were done using the
calcium phosphate precipitation method of Berkner and Sharp
(19). Twenty-four hours prior to transfection, 1.0 x 106 cells
were plated into 100 mm dishes. The following day, the medium
was replaced and the cells were transfected with 10 or 15 µg
plasmid DNA in 125 mM CaCl 2 , 2X HBS (280 mM NaCl/ 1.5
mM Na 2 HPO 4 / 50 mM HEPES Buffer (pH 7.05)). After an
overnight incubation, the DNA precipitate was removed and
replaced with fresh medium. Forty-eight hours after transfection
cells were assayed for transgene expression. Transfection
efficiency was monitored by observation of GFP expression in
control cells transfected with a GFP-expression plasmid.
Vif inhibition assay
To determine the ability of the hammerhead ribozyme
Vif5113 to inhibit vif expression, a transient inhibition assay was
employed. For this, 293T cells were co-transfected with pCMVVifFLAG and either pSRP5113 or pSRP5113∆. HIV-1 vif was

Protein Isolation
Total protein was isolated from the transfected cells
using RIPA buffer containing protease inhibitors (PBS/0 .1 %
SDS/1 % NP40/0.5 % sodium deoxycholate/1 µg/µL aprotinin/1
µg/µL leupeptin/1 µg/µL pepstatin/1 µM NaF/0.1 µM NaVO 4 /
0.1 mg/mL PMSF). Forty-eight hours following transfection, the
medium was aspirated, and the cells were washed 2X with 4 mL
ice cold PBS. One milliliter of ice cold PBS was added to each
dish, the cells were scraped from the plate and transferred to a
microcentrifuge tube. The cells were centrifuged at 14,000 rpm
for 2 minutes, the supernatant was removed, and the pellet was
resuspended in 200 µL RIPA buffer.
The lysate was
homogenized by passing through a 1 mL syringe with a 21 gauge
needle. The lysate was incubated on ice for 60 minutes with
mixing every 10 minutes. Subsequently, the lysate was spun at
14,000 rpm for 20 min at 4°C, and the supernatant was
transferred into a new microcentrifuge tube. The isolated protein
was stored at -20°C.
Protein concentrations were determined using the
Bradford assay (BioRad). Briefly, 5 µL of each protein sample
was added to a microplate well along with 250 µL of room
temperature 1X Bradford reagent. The samples were mixed,
incubated for five minutes at RT, and read on the microplate
reader at 595 nm. Protein concentrations and total protein were
determined using the standard curve generated from BSA
standards.
SDS PAGE and Transfer
Protein samples from transfected 293T cells were
thawed on ice and 50 µg of each were combined with an equal
volume of 2X treatment dye (95% formamide/0.025%
SDS/0.025% bromophenol blue/0.025% xylene cyanol
FF/0.5 mM EDTA). For the positive control generated by
transfecting with pCMV-VifFLAG alone, 28 µg of total protein
was added due to a smaller yield in this sample. The samples
were heated to 100°C for 3 minutes to denature the proteins and
immediately quenched on ice. The proteins were separated by
molecular weight in a 12 % polyacrylamide gel in 1X Trisglycine buffer (21). The gel was run at 8 volts/cm (60 V) until
the treatment dye reached the resolving gel. The voltage was
then increased to 15 volts/cm (105 V) to separate the proteins.
The separated proteins were transferred using a semi-dry
apparatus (Owl Scientific) to a PVDF membrane. Briefly, a
PVDF membrane was cut to equal the size of the resolving gel
and activated by soaking in methanol for 3 minutes. Six pieces of
similarly sized filter paper were soaked in Towbin buffer (25 mM
Tris/192 mM glycine/10 % methanol/ 0.1 % SDS). The gel,
membrane, and filter paper were stacked according to the
manufacturer’s protocol, and the proteins were transferred at
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70mA for 2 hours. The membrane was immediately incubated in
Ponceau Stain (0.5 g Ponceau-S in 1 % acetic acid) for 5 minutes
and subsequently incubated with Ponceau destain (1 % acetic
acid) until the bands were visible.
Western Blot
The membrane was blocked in PBS/5% powdered milk
overnight at 4°C. The following day, the membrane was washed
2X with PBS for 2 minutes per wash, and incubated in 10 mL
PBS containing 20 µg anti-FLAG M2 antibody (Stratagene) at
room temperature with gentle rocking for one hour. This was
followed by two washes with PBS for 2 minutes per wash. The
secondary goat anti-mouse HRP conjugate antibody (Chemicon)
was diluted 1:5000 in blocking solution and added to the
membrane. The membrane was incubated with the secondary
antibody for two hours at room temperature with gentle rocking,
and then washed 3X with PBS for 5 minutes per wash. The ECL
detection reagent (Amersham) was prepared and added to the
membrane. The membrane was incubated at room temperature
for 5 minutes, excess reagent was drained away, and the
membrane was wrapped in plastic. The blot was placed in a
cassette with X-ray film (Kodak) and allowed to expose the film
overnight. The film was hand developed using Kodak reagents.

Results
The HIV-1 NL43 vif genomic sequence was analyzed
for the presence of potential hammerhead ribozyme target sites.
One site, a pGUC located at nucleotide 5113 was used to design
an anti-vif hammerhead ribozyme. This ribozyme and its noncatalytic control (Figure 1) were synthesized and cloned into the
retroviral vector, pSuper.retro.puro. Sequencing was used to
verify the ribozyme sequence in the resulting plasmids:
pSRP5113 and pSRP5113∆ (Figure 2).

Figure 2. The retroviral vector pSRP5113. An anti-vif ribozyme targeted
to nucleotide 5113 of the HIV NL43 sequence was cloned into the
retroviral vector, pSuper.retro.puro. The resulting vector is shown. A
similar vector was constructed that expresses a non-catalytic form of the
ribozyme, pSRP5113∆.

The ability of the Vif5113 hammerhead ribozyme to
reduce expression was analyzed using a vif inhibition assay. For
this, two series of co-transfections were carried out in 293T cells
using either pSRP5113 or pSRP5113∆ and the HIV vif expression
plasmid, pCMV-VifFLAG. The first series of co-transfections
included 5 µg of pSRPVif5113 or pSRP5113∆ and 5 µg of
pCMV-VifFLAG. A second series of co-transfections included

10 µg of either pSRPVif5113 or pSRPVif5113∆ and 5 µg of
pCMV-VifFLAG. A 5 µg transfection of a GFP-expressing
plasmid served as a negative control.
The intracellular cleavage ability of the anti-vif
ribozyme was analyzed by Western blot. Forty-eight hours after
each transfection series, total protein was obtained from the cells
and 50 µg of each was separated using a 12% polyacrylamide gel.
The separated proteins were transferred to a PVDF membrane
and probed using an anti-FLAG antibody. The resulting blot was
analyzed to determine the relative levels of vif expression. A
band present at 23 kD was assumed to be HIV Vif (Figure 3).
Con(-)

1

2

3

4

Figure 3. Analysis of vif expression. 293T cells were transfected as
follows: Con(-) – GFP; lane 1 – 1:1 pSRPVif5113 to pCMV-VifFLAG;
lane 2 – 1:1 pSRPVif5113∆ to pCMV-VifFLAG; lance 3 – 2:1 pSRP5113
to pCMV-VifFLAG; and lane 4 – 2:1 pSRP5113∆ to pCMV-VifFLAG.
These results indicated that at the 1:1 ratio, the catalytic ribozyme,
Vif5113 reduced vif expression.

Transfection of 293T cells with a 1:1 mixture of the
catalytic ribozyme, pSRP5113 and pCMV-VifFLAG indicated a
reduction of vif activity (Figure 3, compare lanes 1 and 2). No
such decrease in vif expression was observed when the ribozyme
was transfected at a 2:1 ratio (pSRP5113 to pCMV-VifFLAG).
In this instance the level of vif expression in cells transfected with
the catalytic and non-catalytic ribozymes appeared to be the
same. (Figure 3, compare lanes 3 and 4). This produced a
confounding result, which has yet to be fully resolved.

Discussion
HIV-1 vif encodes a protein that neutralizes an
inhibitory host defense mechanism mediated by apolipoprotein B
mRNA-editing
enzyme-catalytic
polypeptide-like
3G
(APOBEC3G) (8). This protein is a cellular cytidine deaminase
that is encapsulated into assembling virions in the absence of vif
and is inhibitory during the next round of viral replication. Vif
neutralizes APOBEC3G by reducing its translation and by rapid
degradation of the native protein (10).
Because Vif inhibits APOBEC3G, its cleavage by
hammerhead ribozymes may decrease the infectivity of HIV-1
virions. To test this hypothesis an anti-Vif ribozyme targeted to
nucleotide 5113 within the HIV NL43 vif open reading frame and
its non-catalytic control were cloned into the retroviral vector
pSuper.retro.puro for tissue culture analysis. Our preliminary
analysis suggested that the ribozyme was able to decrease vif
expression in a transient assay. This was supported by a series of
co-transfections using a 1:1 ratio of ribozyme and vif expression
plasmids. However, a similar series of co-transfections using a
2:1 ratio of these plasmids produced conflicting results. In this
second transfection series, the samples revealed bands of
approximate equal intensity suggesting that the ribozyme had no
effect on vif expression.
However, after further analysis it was determined that
there were discrepancies in the total amount of protein added to
lane 2 (1:1 pSRP5113∆ to pCMV-VifFLAG) and 3 (2:1
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pSRP5113 to pCMV-VifFLAG). In both cases the amount of
protein was determined to be approximately 50% less than
originally calculated. Notwithstanding, when comparing the 1:1
catalytic transfection, the data suggest that the ribozyme may be
inhibiting vif expression (Figure 3, compare lane 1 and 2). With
more protein in the Vif5113 sample (lane 1) as compared to the
Vif5113∆ samples (lane 2), the differences are even greater than
at first appeared. This also holds true when comparing lane one
(Vif5113) with the other sample transfected with the noncatalytic ribozyme (lane 4). Importantly, approximately equal
amounts of protein were loaded in these two lanes (1 and 4).
These data suggest that the ribozyme may be reducing vif
expression in this cellular model. However; the relatively equal
amounts of vif expression observed in lanes 3 and 4 do not
support this conclusion. These two samples were obtained from
cells that contained catalytic and non-catalytic ribozymes
transfected at a 2:1 ratio. Therefore, further analyses are required
to reproduce this data and ascertain the efficiency of ribozymemediated degradation of vif mRNA
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